U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 81 - 90 of 165 results

Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)

Astragalin (kaempferol-3-O-glucoside) is extracted from many traditional herbs and medicinal plants. Astragalin extracted from persimmon and Rosa agrestis leaves has anti-atopic dermatitis and antioxidant activity. Several biological functions of astragalin have been studied, including inhibition of prostaglandin E2 production and angiotensin converting enzyme activity. It has been reported that astragalin has the inhibitory effect on NO and tumor necrosis factor (TNF)-α production in Raw 264.7 cells. Astragalin is a flavonoid with anti-inflammatory activity. It may be a promising cancer therapeutic drug and it has the potential of preventing atherosclerosis formation.
Status:
Other

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
US Previously Marketed
First approved in 2003

Class (Stereo):
CHEMICAL (ABSOLUTE)



Abarelix is a synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Used in the palliative treatment of advanced prostate cancer. Abarelix is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis. Abarelix binds to the gonadotropin releasing hormone receptor and acts as a a potent inhibitor of gonadotropin secretion. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.
Status:
US Previously Marketed
Source:
STAVUDINE; LAMIVUDINE by PHARMACARE LTD
(2009)
Source URL:
First approved in 1994

Class (Stereo):
CHEMICAL (ABSOLUTE)



Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Stavudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. Stavudine is used for the treatment of human immunovirus (HIV) infections. Stavudine is sold under the brand name Zerit among others.
Status:
US Previously Marketed
Source:
LENIC WITH NIACIN LINOLEIC ACID by CROOKES-BARNES
(1961)
Source URL:
First marketed in 1921
Source:
linoleic acid
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)



Linoleic acid is a naturally occurring omega-6 essential fatty acid, present in a variety of foods, including the oils. Linoleic acid is a precursor for arachidonic acid biosynthesis; on the first enzymatic step of the pathway involves delta-6-desaturase, which converts linoleic acid to gamma-lenolenic acid. Linoleic acid has beneficial effects on human skin and hair. Replacement of saturated fat with linoleic acid is advocated to improve serum lipoprotein profiles and reduce the risk of coronary artery disease. Linoleic acid was tested in clinical trilas as a possible remedy against multiple sclerosis.